

Supplemental Tables for:

Real-World Assessment of Clinical Outcomes among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium (IMDC) Risk Group

Daniel Heng et al.

**Table S1.** Reasons for Treatment Discontinuation among Patients with Clear Cell mRCC who Received First-Line Sunitinib Since 2010, Stratified by IMDC Prognostic Risk Groups<sup>1</sup>

	Overall	IMDC Prognostic Risk Group		
		Favorable	Intermediate	Poor
	N=1,521	N=248 (16.3%)	N=890 (58.5%)	N=383 (25.2%)
Reasons for treatment discontinuation, n (%)	899	157	536	206
Disease progression	529 (58.8)	91 (58.0)	316 (59.0)	122 (59.2)
Toxicity	235 (26.1)	52 (33.1)	141 (26.3)	42 (20.4)
Other <sup>2</sup>	87 (9.7)	11 (7.0)	54 (10.1)	22 (10.7)
Death	32 (3.6)	2 (1.3)	17 (3.2)	13 (6.3)
Disease progression & toxicity	16 (1.8)	1 (0.6)	8 (1.5)	7 (3.4)

mRCC: metastatic renal cell cancer; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium.

<sup>1</sup>Only patients who discontinued first-line treatment were included.

<sup>2</sup>Other reasons included patient refusal, lack of clinical benefit, loss to follow up, surgery, and transfer of care to other centers.

Supplemental Tables for:

Real-World Assessment of Clinical Outcomes among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium (IMDC) Risk Group

Daniel Heng et al.

**Table S2.** Second-line Treatment among Patients with Clear Cell mRCC who Received First-Line Sunitinib since 2010, Stratified by IMDC Prognostic Risk Groups

	Overall N=915	IMDC Prognostic Risk Group		
		Favorable N=183 (20.0%)	Intermediate N=570 (62.3%)	Poor N=162 (17.7%)
Everolimus	362 (39.6)	61 (33.3)	230 (40.4)	71 (43.8)
Pazopanib	140 (15.3)	28 (15.3)	89 (15.6)	23 (14.2)
Axitinib	133 (14.5)	27 (14.8)	74 (13.0)	32 (19.8)
Nivolumab	102 (11.1)	28 (15.3)	66 (11.6)	8 (4.9)
Sorafenib	64 (7.0)	15 (8.2)	40 (7.0)	9 (5.6)
Sunitinib	49 (5.4)	11 (6.0)	28 (4.9)	10 (6.2)
Investigational drug	26 (2.8)	4 (2.2)	20 (3.5)	2 (1.2)
Temsirolimus	12 (1.3)	1 (0.5)	7 (1.2)	4 (2.5)
Cabozantinib	11 (1.2)	3 (1.6)	7 (1.2)	1 (0.6)
Interferon or interleukin-2	4 (0.4)	1 (0.5)	3 (0.5)	0 (0.0)
Bevacizumab	8 (0.9)	1 (0.5)	5 (0.9)	2 (1.2)
Other <sup>1</sup>	4 (0.4)	3 (1.6)	1 (0.2)	0 (0.0)

mRCC: metastatic renal cell cancer; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium

Notes:

<sup>1</sup>Other includes combination therapies.

Supplemental Tables for:

Real-World Assessment of Clinical Outcomes among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium (IMDC) Risk Group

Daniel Heng et al.

**Table S3.** Clinical Outcomes among Patients with Clear Cell mRCC who Received First-Line Sunitinib Since 2010 with Intermediate IMDC Prognostic Risk

	Number of Patients	Median OS (95% CI), months	Median TTD (95%CI), months
Intermediate with 2 risk factors	427	21.9 (18.5, 25.8)	6.6 (5.6, 7.9)
Intermediate with 1 risk factor	458	35.1 (31.7, 39.6)	10.3 (8.7, 12.0)
Calcium > ULN	21	38.1 (25.8, NR)	22.6 (9.8, 28.3)
Less than 1 year from time of diagnosis to targeted therapy initiation	225	35.6 (31.9, 42.6)	9.2 (8.3, 11.3)
KPS < 80%	27	32.4 (12.0, NR)	13.0 (4.8, 21.5)
Neutrophil > ULN	35	32.3 (17.9, 59.4)	7.5 (3.1, 12.9)
Hemoglobin < LLN	140	31.9 (24.9, 44.8)	10.4 (7.9, 13.2)
Platelet > ULN	10	NR	17.4 (8.3, 27.0)

mRCC: metastatic renal cell cancer; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; OS: overall survival; TTD: time to treatment discontinuation; CI: confidence interval; NR: not reached; KPS: Karnofsky Performance Status; LLN: lower limit of normal; ULN: upper limit of normal